Redeye maintains a positive view of Transtema despite a weak Q1 and cuts in Base Case and forecasts. However, we see several reasons to believe Transtema is on a path to improved profitability from now on and back to organic growth in 2025.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema - Weak Q1 – We Expect Improvements from Here

© Modular Finance, source Nordic Press Releases